Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokerages

Posted by Brenda Bartman on May 20th, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has been given an average recommendation of “Hold” by the eleven brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $41.5556.

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th. Truist Financial cut their price target on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, April 30th. Citigroup boosted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 1st.

Read Our Latest Stock Report on AGIO

Insiders Place Their Bets

In other news, insider Sarah Gheuens sold 2,940 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $102,047.40. Following the sale, the insider owned 80,277 shares of the company’s stock, valued at $2,786,414.67. The trade was a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $109,024.11. Following the completion of the sale, the chief financial officer directly owned 54,998 shares in the company, valued at approximately $1,908,980.58. This represents a 5.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 15,582 shares of company stock valued at $520,405 over the last 90 days. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth $25,000. Assetmark Inc. raised its stake in shares of Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter valued at $40,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $49,000. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $72,000.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $27.73 on Wednesday. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The firm’s 50 day moving average price is $29.60 and its two-hundred day moving average price is $29.77. The firm has a market cap of $1.65 billion, a P/E ratio of -3.82 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. The company’s revenue was up 137.7% on a year-over-year basis. On average, sell-side analysts anticipate that Agios Pharmaceuticals will post -6.19 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.